Trevi Therapeutics (TRVI) Gains from Investment Securities (2018 - 2026)

Trevi Therapeutics' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 28775.0% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 1014.47% YoY), while the FY2025 annual figure was $9.3 million, up 18.58% from the prior year.
• Gains from Investment Securities was $3.2 million for Q1 2026 at Trevi Therapeutics, down from $4.3 billion in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $4.3 billion in Q4 2025 to a low of $2631.0 in Q1 2022.
• Historically, Gains from Investment Securities has averaged $273.3 million across 5 years, with a median of $1.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities slumped 99.92% in 2022, then soared 2065132.86% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $4.5 million in 2022, then tumbled by 99.28% to $32000.0 in 2023, then soared by 556.25% to $210000.0 in 2024, then jumped by 2065132.86% to $4.3 billion in 2025, then slumped by 99.93% to $3.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.2 million (Q1 2026), $4.3 billion (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.